CanSino Biologics, Inc. Class A

CanSino Biologics, Inc. Class A

22.42
HKD
-0.92
(-3.94%)
-2.50EPS
16.28BMarket Cap
Mar 30Next Earn

Total Valuation

HKD

As of June 30, 2024, CanSino Biologics, Inc. Class H carries a market capitalization of 16.28B, placing it among publicly traded companies globally. Its enterprise value stands at 14.85B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap16.28B
Enterprise Value14.85B

Important Dates

CanSino Biologics, Inc. Class H's next confirmed earnings release is scheduled for March 30, 2027.

Earnings Date3/30/2027

Share Statistics

As of June 30, 2024, CanSino Biologics, Inc. Class H has 833.07M shares outstanding.

Shares Outstanding833.07M

Valuation Ratios

These figures are as of June 30, 2024. The price-to-sales ratio is 11.72, and the price-to-book ratio stands at 2.99.

PS Ratio11.72
PB Ratio2.99
P/TBV Ratio3.09

Enterprise Valuation

These figures are as of June 30, 2024. The EV/Sales ratio of 22.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 14.85B versus a market cap of 16.28B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales22.67

Financial Position

As of June 30, 2024, CanSino Biologics, Inc. Class H maintains a current ratio of 2.38, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 43.43, indicating elevated leverage, while an interest coverage ratio of -14.37 demonstrates limited ability to service its debt obligations.

Current Ratio2.38
Quick Ratio1.85
Debt / Equity43.43
Debt / EBITDA-2.26
Interest Coverage-14.37

Financial Efficiency

HKD

Over the twelve months ended June 30, 2024, CanSino Biologics, Inc. Class H posted a negative return on equity (ROE) of -15.80, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.61, reflecting losses generated across the asset base. The company generates approximately 386,782.31 in revenue per employee across its workforce of 1,693.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.28 indicates how many times CanSino Biologics, Inc. Class H sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-15.80
Return on Assets (ROA)-9.61
Revenue Per Employee386,782.31
Employee Count1,693.25
Inventory Turnover1.28

Taxes

HKD

Over the twelve months ended June 30, 2024, CanSino Biologics, Inc. Class H recorded an income tax benefit of -10.02M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -993.63M and -931.24M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-10.02M

Stock Price Statistics

HKD

As of the close on November 17, 2026, CanSino Biologics, Inc. Class H's stock has declined approximately 49.25% over the past 52 weeks. The 50-day moving average sits at 29.01, while the 200-day moving average is 28.94.

52-Week Price Change-49.25%
50-Day Moving Average29.01
200-Day Moving Average28.94

Income Statement

HKD

Over the twelve months ended June 30, 2024, CanSino Biologics, Inc. Class H generated 654.92M in revenue and converted that into -931.24M in net income, yielding earnings per share of -2.50. EBITDA reached -1.04B, while operating income came in at -989.13M.

Revenue654.92M
Gross Profit94.15M
Operating Income-989.13M
Pretax Income-993.63M
Net Income-931.24M
EBITDA-1.04B
EBIT-1.04B
Earnings Per Share (EPS)-2.50

Balance Sheet

HKD

As of June 30, 2024, CanSino Biologics, Inc. Class H holds 3.79B in cash and equivalents against 2.36B in total debt, resulting in a net debt position of 487.48M. Total book value stands at 5.44B, with working capital of 2.83B providing operational flexibility.

Cash & Cash Equivalents3.79B
Total Debt2.36B
Net Debt487.48M
Equity (Book Value)5.44B
Book Value Per Share6.53
Working Capital2.83B

Cash Flow

HKD

These figures cover the twelve months ended June 30, 2024.

Capital Expenditures-519.08M

Margins

Over the twelve months ended June 30, 2024, CanSino Biologics, Inc. Class H posted a gross margin of 14.38, reflecting its pricing power and cost economics. The operating margin of -151.03 and net profit margin of -142.19 provide insight into operational efficiency.

Gross Margin14.38
Operating Margin-151.03
Pretax Margin-151.72
Profit Margin-142.19
EBITDA Margin-159.36

Dividends & Yields

Over the twelve months ended June 30, 2024, CanSino Biologics, Inc. Class H paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.67, meaning CanSino Biologics, Inc. Class H raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-0.67

Scores

As of June 30, 2024, CanSino Biologics, Inc. Class H has an Altman Z-Score of 2.73, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.73